Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.

Fleming, G F; Pagani, O; Regan, M M; Walley, B A; Francis, P A

Fleming, G F; Pagani, O; Regan, M M; Walley, B A; Francis, P A.

Afiliação

Fleming GF; Department of Medicine, The University of Chicago Medical Center, Chicago, USA. Electronic address: gfleming@medicine.bsd.uchicago.edu.
Pagani O; Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva University Hospitals, Swiss Group for Clinical Cancer Research (SAKK), Vaud, Switzerland.
Regan MM; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, USA.
Walley BA; University of Calgary and Canadian Cancer Trials Group, Calgary, Canada.
Francis PA; Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Australia.

Ann Oncol ; 33(6): 658, 2022 06.

Article em En | MEDLINE | ID: mdl-35301096

Assuntos

Neoplasias da Mama; Aminopiridinas; Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos; Benzimidazóis/uso terapêutico; Neoplasias da Mama/tratamento farmacológico; Feminino; Humanos; Antígeno Ki-67; Receptor ErbB-2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google